Prime Global Research, Inc.
Welcome,         Profile    Billing    Logout  
 0 Trials 
4 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hussain, Rubaba
NCT05171673: Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants with Minor Soft Tissue Injury

Completed
3
151
US
Licart™ (diclofenac epolamine) topical system, diclofenac epolamine
IBSA Institut Biochimique SA
Soft Tissue Injuries
06/24
07/24
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting
3
2996
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
NCT06063330: Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects

Completed
1
66
US
RQ-001, Placebo
Red Queen Therapeutics, Inc., PPD
COVID-19, Infectious Disease, Symptomatic COVID-19 Infection Laboratory-Confirmed, SARS CoV 2 Infection
01/24
01/24
NCT05817045: Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19

Completed
N/A
330
US
RD-X19, Sham
EmitBio Inc.
COVID-19
06/24
06/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hussain, Rubaba
NCT05171673: Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants with Minor Soft Tissue Injury

Completed
3
151
US
Licart™ (diclofenac epolamine) topical system, diclofenac epolamine
IBSA Institut Biochimique SA
Soft Tissue Injuries
06/24
07/24
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting
3
2996
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
NCT06063330: Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects

Completed
1
66
US
RQ-001, Placebo
Red Queen Therapeutics, Inc., PPD
COVID-19, Infectious Disease, Symptomatic COVID-19 Infection Laboratory-Confirmed, SARS CoV 2 Infection
01/24
01/24
NCT05817045: Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19

Completed
N/A
330
US
RD-X19, Sham
EmitBio Inc.
COVID-19
06/24
06/24

Download Options